Measuring concentration of serum syndecan-1 to assess vascular endothelial glycocalyx injury during hemodialysis

Measuring concentration of serum syndecan-1 to assess vascular endothelial glycocalyx injury during hemodialysis - Measuring concentration of serum syndecan-1 to assess vascular endothelial glycocalyx injury during hemodialysis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000045020

Enrollment

145

Registered

2024-01-01

Start date

2021-07-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Renal Failure/hemodialysis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who underwent hemodialysis at the Gifu University Hospital between March 2017 and December 2019 were enrolled in the study.

Exclusion criteria

Exclusion criteria: Patients aged <20 years, died, underwent plasma apheresis, plasma exchange and double filtration plasma therapy, and who had not maintained the dry weight were excluded from the analysis.

Design outcomes

Primary

Measure	Time frame
Patients' baseline characteristics are presented as median and interquartile range (IQR) for continuous variables, and frequency and proportion for categorical variables. For the primary analysis, a mixed effect model was used to assess the change in syndecan-1 levels with hemodialysis.	—

Secondary

Measure	Time frame
The difference in syndecan-1 levels before and after hemodialysis in the anticoagulant subgroup was confirmed using paired t-test. A multivariable linear regression analysis was performed to compare the change in syndecan-1 levels before/after hemodialysis and treatment with anticoagulants. The covariates in the regression model were age, sex, dry weight, and dialysis period. In another model, dry weight and dialysis period were simultaneously incorporated into the linear regression model to evaluate the effect of factors during dialysis on levels of syndecan-1. An interaction term was included in the model to confirm the effect of modification of dry weight and dialysis period on the change in levels of syndecan-1. If the interaction term was statistically significant, the effect of dialysis period (or dry weight) on syndecan-1 was determined to be modified by dry weight (or dialysis period). A two-sided P < 0.05 was considered to be statistically significant. Because the test is exploratory and because of concerns about low statistical power, the interaction was evaluated with a two-sided P < 0.1. R version 4.1.0 was used for statistical analyses (www.r-project.org).	—

Measure

Time frame

The difference in syndecan-1 levels before and after hemodialysis in the anticoagulant subgroup was confirmed using paired t-test. A multivariable linear regression analysis was performed to compare the change in syndecan-1 levels before/after hemodialysis and treatment with anticoagulants. The covariates in the regression model were age, sex, dry weight, and dialysis period. In another model, dry weight and dialysis period were simultaneously incorporated into the linear regression model to evaluate the effect of factors during dialysis on levels of syndecan-1. An interaction term was included in the model to confirm the effect of modification of dry weight and dialysis period on the change in levels of syndecan-1. If the interaction term was statistically significant, the effect of dialysis period (or dry weight) on syndecan-1 was determined to be modified by dry weight (or dialysis period). A two-sided P < 0.05 was considered to be statistically significant. Because the test is exploratory and because of concerns about low statistical power, the interaction was evaluated with a two-sided P < 0.1. R version 4.1.0 was used for statistical analyses (www.r-project.org).

—

Countries

Japan

Contacts

Public ContactHideshi Okada

Gifu University Graduate School of Medicine Emergency and Disaster Medicine

hideshi@gifu-u.ac.jp058-230-6448

Outcome results